Drug intelligence / Profile preview

envafolimab + axitinib

Development stage: Unknown
Lead developer: 3D Medicines
Modality: Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Subcutaneous

Overview

Envafolimab + axitinib is a combination therapy being investigated for the treatment of advanced clear cell renal cell carcinoma (ccRCC). Envafolimab is a recombinant humanized single-domain antibody (nanobody) that acts as a programmed death-ligand 1 (PD-L1) inhibitor; it is unique as the first PD-L1 inhibitor formulated for subcutaneous injection. Axitinib is an oral, potent, and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By combining immune checkpoint blockade with anti-angiogenic therapy, this regimen aims to enhance anti-tumor efficacy in treatment-naive patients with metastatic or unresectable kidney cancer. The combination is currently being evaluated in a Phase II clinical study led by Peking Union Medical College Hospital.

Other names: Envafolimab + Axitinib

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on envafolimab + axitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on envafolimab + axitinib.

Explore the full profile